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Abstract
Introduction Earlier work indicates that the cholesterol-lowering
drug, simvastatin, is anabolic to chondrogenic expression of rat
intervertebral disc (IVD) cells, which suggests a potential role for
simvastatin in IVD regeneration. In this study, we expand on our
earlier work to test the effectiveness of simvastatin on disc
degeneration utilizing a rat tail disc degeneration model.
Methods 30 rats that underwent 21 G needle-puncture at rat
tail discs were injected with simvastatin-loaded poly(ethylene
glycol)-poly(lactic acid-co-glycolic acid)-poly(ethylene glycol)
(PEG-PLGA-PEG) gel (5 mg/ml) or vehicle control at 4 weeks
after needle injury. All animals were sacrificed 2 weeks after
simvastatin injection. Bone morphogenetic protein-2 (BMP-2),
aggrecan, collagen type II, and collagen type I messenger
ribonucleic acid (mRNA) expression in the rat nucleus pulposus
(NP) were measured by real-time polymerase chain reaction
(PCR).  In vivo magnetic resonance imaging (MRI) was
performed to monitor changes in disc degeneration. Rat discs
were also assessed by histology using hematoxylin and eosin
(H&E) and safranin O staining. In addition, the NP weight,
glycosaminoglycan (sGAG) and DNA content were also
measured.
Results A single dose of simvastatin loaded in thermo-sensitive
PEG-PLGA-PEG gel injected into the NP had the trend to
increase aggrecan expression and sGAG content, and
significantly increased mRNA levels of BMP-2, collagen type II,
and the differentiation index (the ratio of collagen type II to
collagen type I). The decreased NP weight, T2 intensity, as well
as MRI index in the rat tail discs induced by needle puncture
were significantly reversed after 2 weeks of simvastatin
treatment. In addition, simvastatin treatment also improved
histological changes induced by needle puncture.
Conclusions A single injection of simvastatin loaded in PEG-
PLGA-PEG gel into rat tail discs had the potential to retard or
regenerate the degenerative disc.
Introduction
Intervertebral disc (IVD) degeneration is the leading etiological
contributor to low back pain and other disc disorders, which
can cause significant socioeconomic impact. Disc degenera-
tion often starts with cellular and biochemical changes in the
nucleus pulposus (NP) and annulus fibrosus (AF), resulting in
an imbalance between anabolism and catabolism of disc tis-
sues. NP, the main constituent of the IVD, plays a major role in
maintaining normal function of the IVD. As a consequence, any
cellular, biological, or biochemical changes in the NP ulti-
mately deteriorate disc function, leading to disc degeneration.
Despite its high prevalence, the current treatments for degen-
erative disc disease, including steroid injection [1,2], physical
therapy [3,4], intradiscal electrothermal therapy [5,6] and inva-
sive-surgical intervention, are limited to ameliorating symp-
AF: annulus fibrosus; BMP: bone morphogenetic protein; G: gauge; GAPDH: glyceraldehyde 3-phosphate dehydrogenase; H&E: hematoxylin and 
eosin; IL-1β: interleukin-1β; IVD: intervertebral disc; MMP: matrix metalloproteinase; MRI: magnetic resonance imaging; NP: nucleus pulpous; PBS: 
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toms and do not address the etiological problem [7]. With the
recent advances in recombinant therapeutic proteins [8,9] bio-
logical repair or regeneration of the degenerative IVD has been
advocated. This novel treatment option appears promising,
because it facilitates synthesis of matrix molecules that com-
pose the IVD structure, and may also help prevent matrix deg-
radation and/or cell death to detain the progression of disc
degeneration.
Many growth factors, such as the bone morphogenetic protein
(BMP) family (BMP-2, Osteogenic protein-1 (OP-1)/BMP-7,
and Growth differentiation factor 5 (GDF-5)), transforming
growth factor-β, insulin-like growth factor-1, and fibroblast
growth factor have been investigated for their potential for bio-
logical repair and have been shown to elicit an anabolic effect
on IVD cells [10-13]. A single injection of OP-1 [14-16] or
GDF-5 [10] into the degenerative disc has been demonstrated
to be reparative to aberrant discal matrices in vivo. However,
concerns still remain about these recombinant human growth
factors, including undesired blood vessel ingrowth in the IVD
and the need to provide supraphysiologic doses to obtain
effectiveness. Moreover, the high cost of these recombinant
proteins can be prohibitive.
Intriguingly, Mundy and colleagues [17] conducted an exami-
nation of more than 30,000 compounds to determine their
effect on expression of the BMP-2 gene. The 3-hydroxy-3-
methylglutaryl coenzyme A reductase inhibitor statin, was the
only compound that specifically increased BMP-2 mRNA in
bone cells in vitro and subsequent bone formation in vivo. Our
previous work initially illustrated that simvastatin stimulated
endogenous BMP-2 expression in rat IVD cells cultured in
vitro, which in turn promoted expression of a chondrogenic
phenotype [18]. The present study serves to further test the
impact of simvastatin on the degenerative disc in a defined ani-
mal model. It has been recognized that needle puncture can
induce mild and progressive disc degeneration that is suitable
for testing potential treatments for degenerative disc disease
[19,20]. In this study, we used a disc degeneration model
developed from our previous work, which can reproduce disc
degeneration in rat tails consistently with less invasive pertur-
bation [21]. The simvastatin-loaded compound was injected
intradiscally and the effect of simvastatin on the degenerative
disc was evaluated by changes in magnetic resonance imag-
ing (MRI), gene expression, and biochemical and histological
assays.
Materials and methods
Animals
Sprague-Dawley rats (three months old) were obtained from
Harlan Laboratories (Indianapolis, IN, USA) and were housed
in groups of three rats per cage. As rats reach their skeletal
maturity before 3 months of age, the concern of IVD remode-
ling due to growth can be eliminated for the selected rats at
the predetermined age used in this study [22,23]. Experiments
were performed in accordance with the Guide for the Care
and Use of Laboratory Animals, and the experimental proto-
cols were approved by the University Committee on the Use
and Care of Animals at the University of Michigan.
Surgical technique
The surgical procedure described previously was followed in
this study [21]. Briefly, anesthesia for all surgical procedures
was achieved and maintained by inhalation of anesthetic iso-
flurane and the operative field was prepared in a sterile fash-
ion. After palpation to determine the disc levels, a small skin
cross-incision was made to help locate disc position for nee-
dle insertion. Co6/Co7 remained undisturbed as the control
level. Fluoroscopy was used to visualize needle penetration
and to ensure that the stab went into the center of the NP. A
21-gauge (G) needle was then inserted in the middle of the
appropriate disc, controlled by a locking forceps clamped at 5
mm from the needle, through the AF into the NP of Co5/Co6
and Co7/Co8, rotated 180°, and held for five seconds.
Simvastatin treatment
Four weeks after stab injury using the 21-G needle, either
poly(ethylene glycol)-poly(lactic acid-co-glycolic acid)-
poly(ethylene glycol) (PEG-PLGA-PEG) gel loaded with 2 μL
of simvastatin (LKT Laboratories, St. Paul, MN, USA) or gel
alone was slowly injected into the NP of Co5/Co6 and Co7/
Co8 randomly using a microsyringe attached to a 31-G nee-
dle. The drug-loaded compound contained simvastatin at a
concentration of 5 mg/mL. The 31-G needle was chosen for
drug injection based on our trial results, because it does not
cause injury leading to disc degeneration. The tri-block PEG-
PLGA-PEG polymer was chosen as the drug vehicle, because
it has the desired properties of being thermo-sensitive, biode-
gradable, biocompatible, and injectable, and it has been dem-
onstrated to extend the duration of drug exposure [24,25]. For
all subsequent experiments, four experiment groups were gen-
erated: the intact control group (without needle puncture,
without gel injection); the stabbed group (with needle punc-
ture, without gel injection); the gel-alone treatment group (with
needle puncture, gel only injection); and the simvastatin treat-
ment group (with needle puncture, gel loaded with simvastatin
injection). At two weeks after the injection of gel loaded with
or without simvastatin, the approached caudal spine levels of
rat tails were assessed.
Quantitative real-time PCR
Total RNA was extracted from the NP using the Trizol (Invitro-
gen, Carlsbad, CA, USA) reagent followed by RNeasy Mini Kit
(Qiagen, Inc., Valencia, CA, USA). Reverse transcription was
carried out at 42°C for 50 minutes using the SuperScript First-
Strand Synthesis Kit (Invitrogen, Carlsbad, CA, USA). Type II
collagen, type I collagen, aggrecan, BMP-2, and glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) gene expression
were quantified by real-time PCR using Gene Amp 7700
Sequence Detection System (Applied Biosystems, FosterAvailable online http://arthritis-research.com/content/11/6/R172
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City, CA, USA). A positive standard curve for each primer was
obtained by real-time PCR with serially-diluted cDNA sample
mixture. Quantities of gene expression of BMP-2, aggrecan,
and type I and type II collagens were calculated with standard
samples and normalized with GAPDH. The amounts of mRNA
expression were presented as a ratio to the intact control
group.
MRI procedures and data processing
At two weeks after injection of either gel loaded with simvas-
tatin or gel alone, the approached caudal spine levels of rat
tails were assessed by MRI. Briefly, rats were anesthetized
with a 2% isoflurane/oxygen mixture throughout the entire MRI
examination. The animal was laid prone and the tail was
straightened in a 7.0 T Varian MR scanner (183 mm horizontal
bore; Varian, Inc., Palo Alto, CA, USA), and body temperature
was maintained at 37°C using circulating heated air. A double-
tuned volume radiofrequency coil was used to scan the tail
region of the rats. Eight serial T2-weighted sagittal images
covering the entire disc area were acquired using a spin-echo
sequence with the following parameters: fat saturation on; rep-
etition time/effective echo time, 3000/30 ms; field of view, 30
× 60 mm; matrix, 128 × 128; slice thickness, 0.5 mm; slice
spacing, 0 mm; number of slices, eight; number of scans, 1
(total scan time 6.24 minutes).
A procedure described previously was followed to quantita-
tively analyze the obtained image slices using Analyze 7.0 soft-
ware (AnalyzeDirect, Overland Park, KS, USA) [21]. The
nucleus region was segmented from the sliced images, fol-
lowed by image reconstruction and volume rendering proce-
dures to generate volumetric images and therefore calculate
each nuclear volume. All image assessments described were
conducted by three independent, blinded observers and the
quantitative data were presented as the mean of the three
evaluations. T2-weighted density as well as MRI index (the
area of NP multiplied by average signal intensity) were quanti-
fied and calculated. For the MR index calculation, the NP area
was defined by an image threshold automatically assigned by
an image analysis software Analyze 7.0, which detects the
default image densities over the acquired regions.
Biochemical analyses
After discs were isolated from each level, a small incision was
created in the AF by a sharp scissor and the entire NP (the
gelatinous tissue) was taken out carefully using a micro scoop
(Circon MicroSurgical, Santa Barbara, CA, USA). The dis-
sected NP was weighed using an electronic scale, and
digested with papain (125 μg/mL in sterile PBS with 5 mM
cysteine. HCl and 5 mM Na2EDTA, pH 6.0) at 60°C for 24
hours. The proteoglycan, mainly sulfated glycosaminoglycan
(sGAG), and the DNA contents in the digested solution were
assayed using the dimethyl-methylene blue method [26] and
Hoechst dye 33258 method [27], respectively.
Histological analysis
After the animals were euthanized, three to four discs from
each group were harvested for histological studies. Each disc,
with 3.5 ± 0.5 mm of the adjacent vertebral bodies, was fixed
in 10% neutral-buffered formalin for one week, decalcified in
22.5% formic acid and 10% sodium citrate for approximately
two to three days. They were then processed for paraffin
embedding and sectioning into sagittal sections (10 μm thick)
using a microtome. Sections were stained with H&E and
safranin O with fast-green counterstaining. Histological
images were analyzed qualitatively under a light microscope
(Olympus BX51; Olympus, Center Valley, PA, USA) at magni-
fications ranging from 4× to 100× to investigate changes in
NP, AF, and endplates. The histological sections were also
graded by blinded observers using the scoring standard
established by Masuda and colleagues [19].
Statistical analysis
All data were expressed as mean ± standard error. The signif-
icance of differences among the means of data for gene
expression, MRI measurement, biochemical parameters, and
histological scores were analyzed using one-way analysis of
variance and Fisher's least significant difference as a post hoc
test. A P-value of less than 0.05 was considered statistically
significant.
Results
mRNA expression of BMP-2
Figure 1 illustrates that BMP-2 mRNA expression in the NP
among the intact control, stabbed, and gel-alone-treated
Figure 1
BMP-2 mRNA expression in the nucleus pulpous of different experi- mental groups at two weeks after drug injection BMP-2 mRNA expression in the nucleus pulpous of different experi-
mental groups at two weeks after drug injection. Discs in the treatment 
groups were injected with either 2 μL of gel alone or gel loaded with 
simvastatin (SIM; 5 mg/mL) at four weeks after disc stab with 21-G 
needle. * P < 0.05 when compared with intact control group,# P < 0.05 
when compared with stabbed group. BMP = Bone morphogenetic pro-
tein.Arthritis Research & Therapy    Vol 11 No 6    Zhang et al.
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groups was not significantly different. When rat discs were
treated with simvastatin, BMP-2 mRNA expression was signif-
icantly increased compared with that of the intact control and
stabbed groups (P < 0.05).
mRNA expression of aggrecan, type I, and type II 
collagens
Groups treated with simvastatin showed an increase in mRNA
expression of aggrecan although the increase did not reach
significance (Figure 2a). However, the mRNA level of type II
collagen, another key phenotypical molecule of chondrogene-
sis, was significantly lower in the stabbed discs when com-
pared with the intact ones (P  < 0.05). When discs were
treated with gel alone, the mRNA level of type II collagen
changed significantly compared with that of the stabbed discs
(P < 0.05). The mRNA level of type II collagen was most ele-
vated in discs treated with the compound loaded with simvas-
tatin. Statistical analysis showed that collagen type II mRNA
Figure 2
mRNA expression of (a) aggrecan, (b) type II collagen, (c) type I collagen, and (d) differentiation index in the nucleus pulpous of different experimen- tal groups at two weeks after drug injection mRNA expression of (a) aggrecan, (b) type II collagen, (c) type I collagen, and (d) differentiation index in the nucleus pulpous of different experimen-
tal groups at two weeks after drug injection. The differentiation index is the ratio of type II to type I collagens. Discs in the treatment groups were 
injected with either 2 μL of gel alone or gel loaded with simvastatin (SIM; 5 mg/mL) at four weeks after the disc stab with 21-G needle. * P < 0.05 
and ** P < 0.01 when compared with intact control group;# P < 0.05 and ## P < 0.01 when compared with stabbed group; + P < 0.05 and ++ P < 
0.01 when compared with gel-alone-treated group.Available online http://arthritis-research.com/content/11/6/R172
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expression was significantly increased in the simvastatin-
treated groups when compared with the other three groups
(Figure 2b; P < 0.05 when compared with intact control and
gel-alone-treated group, and P < 0.01 when compared with
stabbed group).
The mRNA expression of type I collagen that typically reflects
dedifferentiation of chondrocytes was also measured in our
study. The mRNA levels of type I collagen in the stabbed disc
and those treated with gel alone presented an increase at two
weeks after injection. When the stabbed disc was treated with
simvastatin, the mRNA level of type I collagen in this group, on
the other hand, was decreased. However, post hoc compari-
sons indicated there was no significant difference among all
experimental groups (Figure 2c).
The ratio of type II to type I collagens is typically referred to as
a 'differentiation index' of chondrocytes to demonstrate the
propensity for chondrogenesis. As shown in Figure 2d, the dif-
ferentiation index in the stabbed control group was signifi-
cantly decreased when compared with that of the intact
control group (P < 0.05). There was no significant difference
between the differentiation indices of the stabbed control and
gel-treated groups. However, the index of the simvastatin-
treated group was significantly higher than all other groups at
time of the investigation (P < 0.01).
MRI assessment
Representative T2-weighted, midsagittal images of the
approached rat caudal disc are shown in Figure 3. At two
weeks after injection, MRIs of the NP in the simvastatin-treated
group showed stronger signal intensities than those in the
stabbed group and the group treated with hydrogel alone (Fig-
ure 3a). When compared with the intact control group, the T2
density and MRI index of the stabbed group were significantly
decreased (P  < 0.01). T2 density in the gel-alone-treated
group showed a significant decrease when compared with the
stabbed group (P < 0.05). However, no significant change in
MRI index was noticed between the stabbed and the gel-
treated groups. In the simvastatin-treated group, the T2 sig-
nals and MRI indices in the perturbed discs were all signifi-
cantly increased at two weeks after injection compared with
those of the stabbed group (P < 0.05) and the gel-alone-
treated group (P < 0.01; Figures 3b and 3c).
Biochemical analyses
The weight of a NP normally decreases with progression of
disc degeneration. The weight of the NP in the intact control
group was 3.8 ± 0.33 mg/disc. It dropped to 1.72 ± 0.24 mg/
disc in the stabbed control group, which showed a significant
difference compared with intact controls (P < 0.01). No signif-
icant difference was noticed between the stabbed and the gel-
alone-treated groups. After stabbed discs were treated with
simvastatin, the weight of the NP significantly increased com-
pared with the stabbed control group and gel-alone-treated
group (P < 0.05; Figure 4a).
The sGAG content in the stabbed groups was lower than that
in the intact control group. The difference, however, was not
statistically significant between the two groups. The sGAG
content in the gel-alone-treated discs decreased significantly
as compared with the intact control group (P < 0.05). Treat-
ment with simvastatin increased sGAG content in the stabbed
discs; however, the increase did not reach statistical signifi-
cance (Figure 4b).
To determine whether simvastatin cell viability, the DNA con-
tent in the affected NP was measured. As shown in Figure 4c,
Figure 3
Representative MRI scans and quantitative analysis of T2 density and MRI index of different experimental groups at two weeks after drug injection Representative MRI scans and quantitative analysis of T2 density and MRI index of different experimental groups at two weeks after drug injection. 
Discs in treatment groups were injected with either 2 μL of gel alone or gel loaded with simvastatin (SIM; 5 mg/mL) at four weeks after the disc stab 
with 21-G needle. ** P < 0.01 when compared with intact control group;# P < 0.05 when compared with stabbed group; ++ P < 0.01 when com-
pared with gel-alone-treated group. MRI = magnetic resonance imaging.Arthritis Research & Therapy    Vol 11 No 6    Zhang et al.
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DNA content in the stabbed and gel-alone-treated groups was
significantly decreased compared with that of the intact con-
trol (P < 0.05). Two weeks of simvastatin treatment resulted in
an increase in the DNA content that had decreased due to
needle puncture. Post hoc analysis did not show a significant
difference between the simvastatin-treated group and gel-
alone-treated group.
Histological changes
In the intact disc stained by H&E, the boat-shaped NP com-
prised at least one-half of the disc area at the midsagittal
cross-section. The AF was intact and the border between the
AF and the NP was clearly defined. In the stabbed group, NP
area in the 21-G needle-stabbed disc decreased and became
irregular, with some areas densely staining. Discs in the gel-
alone-treated group still displayed features of disc degenera-
tion to a certain extent. Conversely, the cell distribution and the
extracellular matrix alignment in the 21 G-needle stabbed ani-
mals treated with simvastatin were more even and regular than
those in the stab and gel-alone groups. The NP area in the
intact disc stained strongly with safranin O. In the stabbed
discs, the positively stained area decreased. However, the
stained levels were not homogenous, as some regions stained
very densely compared with surrounding vicinities. The posi-
tively stained area in the gel-alone-treated group was much
smaller and weaker. When the disc was treated with simvasta-
tin, the NP area was stained more positively than those in the
gel-alone-treated group (Figure 5).
Semi-quantitative histological scores were 4 ± 0 for intact
control, 10 ± 1.15 for stabbed control, 11.25 ± 0.48 for gel-
alone-treated group, and 7.75 ± 1.49 for simvastatin-treated
group. Statistical analysis showed the histological scores of
the stabbed discs in the stabbed and gel-alone-treated groups
significantly increased when compared with intact control
discs (P < 0.01). There was no significant difference in histo-
logical scores between the stabbed and gel-alone-treated
groups. The histological score of the simvastatin-treated
group, however, was significantly lower than the gel-alone-
treated group (P < 0.05, Figure 6).
Discussion
IVD degeneration is mostly characterized by changes in disc
morphology and composition of the extracellular matrix, as well
as loss of disc cells and water content. To achieve optimal disc
repair, the ideal therapy should preserve the intact architecture
of the disc tissue as much as possible, while increasing the
synthesis of water-absorbing molecules, such as type II colla-
gen and proteoglycan, to restore its 'shock-cushion' function.
Most of the new biology-based strategies for disc repair are
based upon these principles, including autologous cell trans-
plantation, growth factor injection, or gene delivery. The
present study provides a promising alternative that is poten-
tially more easily translated to the clinical setting. Our results
show that a single dose of simvastatin loaded in PEG-PLGA-
PEG gel injected into the NP of rat discs up-regulates mRNA
levels of collagen type II and the differentiation index (the ratio
of type II to type I collagen). The improvements were also evi-
dent in the changes in NP weight, histological morphology,
and MRI at certain significant levels.
Our previous study demonstrated that simvastatin promoted
expression of a chondrogenic phenotype of rat IVD cells,
mainly through the up-regulated BMP-2-mediated pathway
[18]. To determine if the stimulation of BMP-2 mRNA expres-
sion can be replicated in vivo by simvastatin, gene expression
of BMP-2 in NP tissue was initially measured. The results indi-
cated that injection of simvastatin up-regulated BMP-2 mRNA
Figure 4
Weight, sGAG, and DNA content in the NP of different experimental groups at two weeks after drug injection Weight, sGAG, and DNA content in the NP of different experimental groups at two weeks after drug injection. Discs in the treatment groups were 
injected with either 2 μL of gel alone or gel loaded with simvastatin (SIM; 5 mg/mL) at four weeks after disc stab with 21-G needle. * P < 0.05 and 
** P < 0.01 when compared with intact control group;# P < 0.05 when compared with stabbed group; + P < 0.05 when compared with gel-alone-
treated group. NP = nucleus pulpous; sGAG = glycosaminoglycan.Available online http://arthritis-research.com/content/11/6/R172
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levels, thus promoting an anabolic mechanism for IVD repair.
Earlier studies have also proposed a similar concept to facili-
tate IVD repair, although the methods involved either direct
exogenous supplementation of BMP-2 [12,28,29] or endog-
enous up-regulation of BMP-2 with the over-expression of LIM
mineralization protein-1 [30].
The anabolic stimulus primarily included significant increases
in mRNA expression of type II collagen, and the ratio of type II
to type I collagen. Previous studies indicated an increase in
type I collagen and a reduction in type II collagen were present
in the degenerating NP [31]. The 'differentiation index', which
is defined by the ratio of gene expression of type II to type I col-
lagen, has become a method to track the functionality of
chondrocytes (or chondrocyte-like cells in the case of NP) and
can be used as a reference to measure degeneration of carti-
laginous tissues [32].
One interesting observation from our results involved chondro-
genic expression stimulated by the delivered simvastatin.
When normal IVD cells were treated with simvastatin, the
mRNA expression of both aggrecan and type II collagen were
significantly up-regulated [18], whereas only the mRNA level
of type II collagen in the degenerative NP increased after sim-
vastatin treatment in the present in vivo study. Due to the
Figure 5
Representative H&E (4× and 20×) and safranin O stainings (10×) of disc samples from different experimental groups at two weeks after drug injec- tion Representative H&E (4× and 20×) and safranin O stainings (10×) of disc samples from different experimental groups at two weeks after drug injec-
tion. Discs in the treatment groups were treated with either 2 μL of gel alone or gel loaded with simvastatin (SIM; 5 mg/mL) at four weeks after disc 
stab with 21-G needle. SO = safranin O.
Figure 6
Histological scores of different experimental groups at two weeks after  drug injection Histological scores of different experimental groups at two weeks after 
drug injection. Discs in the treatment groups were injected with either 2 
μL of gel alone or gel loaded with simvastatin (SIM; 5 mg/mL) at four 
weeks after disc stab with 21-G needle. Changes in histological 
appearance were assessed semi-quantitatively. * P < 0.05 and ** P < 
0.01 when compared with intact control group;+ P < 0.05 when com-
pared with gel-alone-treated group.Arthritis Research & Therapy    Vol 11 No 6    Zhang et al.
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changes in the notochord cells during the process of disc
degeneration [33] and the different susceptibility to the stimuli
between notochord cells and chondrocyte-like cells [34], the
discrepancy in the responsiveness of normal and degenerative
rat IVD cells to simvastatin may imply that the degree of disc
degeneration and/or the cell components may affect the
response of treated cells. Further studies are required to
explore more details before any conclusions can be drawn.
The efficacy of simvastatin was also demonstrated by changes
in sGAG content, MRI analysis, and NP weight. It should be
highlighted that although the MRI and histological assays
showed evidence of disc degeneration in the stabbed group,
the sGAG content of this group was not significantly reduced
compared with the intact control. This phenomenon has been
observed in previous studies, and has been attributed to con-
densation of the extracellular matrix as an early response to the
onset of disc degeneration [21,23,35]. In the group treated
with gel alone, none of the measurements were improved.
Conversely, the MRI, histological assessment, and NP weight
were significantly improved in the simvastatin-treated group.
Our previous study raised the concern of decreased cell via-
bility, despite the significant augmentation of chondrogenesis
in the IVD cells by simvastatin in vitro [18]. In the present
study, a similar finding was not observed according to DNA
analysis. It is likely that the use of PEG-PLGA-PEG hydrogel
to deliver simvastatin minimized the likelihood of exposing cells
to a transiently high concentration of the drug at the time of
injection. This tri-block polymer has been used extensively as
a carrier for controlled drug or gene delivery [24,36,37]. Our
pilot data in a separate study also demonstrated that the
release profile of simvastatin from the PEG-PLGA-PEG gel in
vitro was steady and sustainable (data not shown). In addition,
the polymer was chosen for its property of sol-gel phase tran-
sition, and slow degradation [38]. After simvastatin is incorpo-
rated into the liquid gel and injected into the NP, the
compound rapidly converts to the gel phase as soon as it
reaches body temperature. Within the gel format, it would be
expected that the exposure of simvastatin to the IVD cells can
be confined to the discal core and the delivery can be sus-
tained [39]. The safety concern of the gel is likely to be mini-
mal, because PEG-PLGA-PEG hydrogel has been well
characterized and is currently undergoing phase I clinical trials
for the treatment of breast cancer [40].
It should be noted that a recent study showed different results
by introducing BMP-2 intradiscally for 12 weeks in a rabbit
degenerative disc model. In that study, the discs treated with
BMP-2 developed degenerative changes [41]. The differing
results may reflect the fact that the delivered dose and the
induced concentration of BMP-2 were quite different. The
direct injection of 0.1 mg of BMP-2 was supraphysiological
compared with the endogenous level of BMP-2 induced by
simvastatin in our study. It has been reported that a dose of 0.1
mg of BMP-2 is in the optimal range for successful posterola-
teral fusion in rabbits [42]. However, for achieving cartilage
repair, BMP-2 was used at lower doses (1 to 15 μg) [43-45]
or by over-expression of BMP-2 using a virus vector [46]. In
our previous study, the amount of induced BMP-2 (60 to 140
pg/mL) was sufficient to promote chondrogenic expression in
the IVD cells (unpublished publication). Similarly, the results of
this study suggest that the concentration of induced BMP-2
by simvastatin treatment is in the therapeutic range to achieve
disc repair. The degree of disc degeneration may have also
resulted in the conflicting observed responses to BMP-2 stim-
uli. In the rabbit study by Huang and colleagues [41], the
model used to simulate disc degeneration involved a full-thick-
ness lesion created by blade penetration, whereas a mild and
slower progression of disc degeneration occurred in the
stabbed disc method used in our study. It has been shown that
the BMP-2 receptor BMPRII was expressed predominantly in
the AF associated with severe disc degeneration in our previ-
ous study [21], and the BMP-2 uptake at this site (where
fibroblast-like cells reside) typically leads to osteophyte forma-
tion, because it has been shown in several studies that exoge-
nous BMP-2 induced the BMPRII expression of ligamentous
fibroblasts and, in turn, initiated endochondral ossification
[47,48].
In addition to anabolism of chondrogenesis by simvastatin,
there is evidence that statins can elicit anti-inflammatory
actions in activated human chondrocytes [49], IL-1β-stimu-
lated human chondrocytes [50], and experimental osteoarthri-
tis in rabbits [51] by inhibiting the level of matrix
metalloproteinase (MMP). For disc cells, increased MMPs
have been found to promote disc degeneration [52-54]. A
recent study even specified that the biochemical mediators of
inflammation and tissue degradation including MMP-3, IL-1β
and inducible nitric oxide synthase were significantly
increased along with the disc degeneration that was induced
by needle puncture [55]. Of interest is whether simvastatin
can also help suppress catabolism of chondrogenesis in
degenerative disc, and thus, is the focus of our next study.
Conclusions
Local injection of a simvastatin-loaded PEG-PLGA-PEG com-
pound was preliminarily found to promote autogenous chon-
drogenic disc repair and retard disc degeneration, which
provides an alternative strategy for biological disc repair in a
less expensive and easily applied method. Due to the limitation
that the rat model may differ from the scheme of human disc
degeneration, particularly in biomechanical functions and cel-
lular components, future research including a long-term treat-
ment study in this animal model as well as in a large animal
model will be required to demonstrate more definitively that
intradiscal injection of simvastatin would be useful for the
retardation of disc degeneration.Available online http://arthritis-research.com/content/11/6/R172
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